不确定期慢性HBV感染者应积极抗病毒治疗

王静月; 黄缘

doi:10.3969/j.issn.1001-5256.2021.11.008

不确定期慢性HBV感染者应积极抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.008

王静月,
黄缘^,

清华大学附属北京清华长庚医院肝胆胰内科，北京 102218

详细信息

通信作者:
黄缘，huangy9815@163.com

中图分类号: R512.62
计量
- 文章访问数: 440
- HTML全文浏览量: 67
- PDF下载量: 93
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-30
- 录用日期: 2021-08-30
- 出版日期: 2021-11-20

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy

Jingyue WANG,
Yuan HUANG^,

Department of Hepatology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 不确定期 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Indeterminate Phrase /
- Therapeutic

HTML全文

参考文献(10)

[1]	HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Online ahead of print]
[2]	SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802.
[3]	GHANY MG, WAHED A, FELD JJ, et al. Indeterminant phenotypes of HBeAg-negtive chronic hepatitis B and predictors of transition to inactive or active disease: Outcomes of a prospective North Anerican Cohort[C]. AASLD 2020: Abstract (poster 764).
[4]	YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
[5]	BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613.
[6]	TESTONI B, LEBOSSÉ F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625. DOI: 10.1016/j.jhep.2018.11.030.
[7]	CHEN EQ, WANG ML, TAO YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat, 2019, 26(5): 586-595. DOI: 10.1111/jvh.13061.
[8]	LOGGI E, VUKOTIC R, CONTI F, et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(5): 568-575. DOI: 10.1111/jvh.13054.
[9]	BRUNETTO MR, CAREY I, MAASOUMY B, et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis[J]. Aliment Pharmacol Ther, 2021, 53(6): 733-744. DOI: 10.1111/apt.16258.
[10]	DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.